WallStreetZenWallStreetZen

NASDAQ: KZR
Kezar Life Sciences Inc Stock

$0.64-0.04 (-5.88%)
Updated Jul 18, 2024
KZR Price
$0.64
Fair Value Price
$1.44
Market Cap
$46.81M
52 Week Low
$0.54
52 Week High
$2.55
P/E
-0.46x
P/B
0.28x
P/S
9.38x
PEG
N/A
Dividend Yield
N/A
Revenue
$7.00M
Earnings
-$101.33M
Gross Margin
100%
Operating Margin
-1,424.99%
Profit Margin
-1,447.6%
Debt to Equity
0.18
Operating Cash Flow
-$84M
Beta
0.88
Next Earnings
Aug 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A

KZR Overview

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how KZR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

KZR ($0.64) is undervalued by 55.35% relative to our estimate of its Fair Value price of $1.44 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
KZR ($0.64) is significantly undervalued by 55.35% relative to our estimate of its Fair Value price of $1.44 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
KZR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KZR due diligence checks available for Premium users.

Be the first to know about important KZR news, forecast changes, insider trades & much more!

KZR News

Valuation

KZR fair value

Fair Value of KZR stock based on Discounted Cash Flow (DCF)
Price
$0.64
Fair Value
$1.44
Undervalued by
55.59%
KZR ($0.64) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KZR ($0.64) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KZR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

KZR price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.46x
Industry
-26.99x
Market
29.86x

KZR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.28x
Industry
6.19x
KZR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

KZR's financial health

Profit margin

Revenue
$0.0
Net Income
-$21.7M
Profit Margin
0%
KZR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
KZR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$199.1M
Liabilities
$30.0M
Debt to equity
0.18
KZR's short-term assets ($185.61M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KZR's short-term assets ($185.61M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KZR's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
KZR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$22.9M
Investing
$20.4M
Financing
$0.0
KZR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

KZR vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
KZR$46.81M-5.30%-0.46x0.28x
NXTC$47.00M-4.55%-0.74x0.47x
BTAI$46.54M-3.13%-0.24x-0.64x
TARA$46.53M-1.74%-0.60x0.80x
LSB$46.53M+4.17%N/A0.10x

Kezar Life Sciences Stock FAQ

What is Kezar Life Sciences's quote symbol?

(NASDAQ: KZR) Kezar Life Sciences trades on the NASDAQ under the ticker symbol KZR. Kezar Life Sciences stock quotes can also be displayed as NASDAQ: KZR.

If you're new to stock investing, here's how to buy Kezar Life Sciences stock.

What is the 52 week high and low for Kezar Life Sciences (NASDAQ: KZR)?

(NASDAQ: KZR) Kezar Life Sciences's 52-week high was $2.55, and its 52-week low was $0.54. It is currently -74.78% from its 52-week high and 19.52% from its 52-week low.

How much is Kezar Life Sciences stock worth today?

(NASDAQ: KZR) Kezar Life Sciences currently has 72,801,359 outstanding shares. With Kezar Life Sciences stock trading at $0.64 per share, the total value of Kezar Life Sciences stock (market capitalization) is $46.81M.

Kezar Life Sciences stock was originally listed at a price of $17.75 in Jun 21, 2018. If you had invested in Kezar Life Sciences stock at $17.75, your return over the last 6 years would have been -96.38%, for an annualized return of -42.48% (not including any dividends or dividend reinvestments).

How much is Kezar Life Sciences's stock price per share?

(NASDAQ: KZR) Kezar Life Sciences stock price per share is $0.64 today (as of Jul 18, 2024).

What is Kezar Life Sciences's Market Cap?

(NASDAQ: KZR) Kezar Life Sciences's market cap is $46.81M, as of Jul 19, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Kezar Life Sciences's market cap is calculated by multiplying KZR's current stock price of $0.64 by KZR's total outstanding shares of 72,801,359.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.